• FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

  • 2024/06/21
  • 再生時間： 57 分
  • ポッドキャスト

FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.

    Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.

    In this episode, we discuss:

    • The FDA advisory committee process and its implications for drug approvals
    • Functional unblinding and expectancy effects in psychedelic clinical trials
    • Potential impacts on the broader psychedelic medicine industry
    • The future of psychedelic-assisted psychotherapy protocols
    • Neuroplastogen development and non-hallucinogenic approaches
    • Challenges around therapy, safety, and regulatory pathways for psychedelic medicines

    Credits:

    Created by Greg Kubin and Matias Serebrinsky
    Host: Matias Serebrinsky & Greg Kubin
    Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner

    Find us at businesstrip.fm and psymed.ventures
    Follow us on Instagram and Twitter!
    Theme music by Dorian Love
    Additional Music: Distant Daze by Zack Frank
    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.

Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.

In this episode, we discuss:

  • The FDA advisory committee process and its implications for drug approvals
  • Functional unblinding and expectancy effects in psychedelic clinical trials
  • Potential impacts on the broader psychedelic medicine industry
  • The future of psychedelic-assisted psychotherapy protocols
  • Neuroplastogen development and non-hallucinogenic approaches
  • Challenges around therapy, safety, and regulatory pathways for psychedelic medicines

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank
心理学 代替医療・補完医療 衛生・健康的な生活 科学
続きを読む 一部表示

FDA advisors say no to MDMA. What’s the impact? With Josh Hardmanに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。